Your browser is no longer supported. Please, upgrade your browser.
Settings
ARGS Argos Therapeutics, Inc. daily Stock Chart
ARGS [NASD]
Argos Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.87 Insider Own1.00% Shs Outstand61.43M Perf Week-51.00%
Market Cap30.10M Forward P/E- EPS next Y-0.80 Insider Trans23.49% Shs Float21.48M Perf Month-63.70%
Income-53.00M PEG- EPS next Q-0.33 Inst Own24.80% Short Float13.65% Perf Quarter-89.46%
Sales0.90M P/S33.45 EPS this Y54.70% Inst Trans9.45% Short Ratio4.79 Perf Half Y-90.08%
Book/sh0.09 P/B5.44 EPS next Y31.60% ROA-67.30% Target Price1.60 Perf Year-90.98%
Cash/sh0.86 P/C0.57 EPS next 5Y- ROE- 52W Range0.48 - 13.97 Perf YTD-90.00%
Dividend- P/FCF- EPS past 5Y-3.90% ROI-96.30% 52W High-96.46% Beta-
Dividend %- Quick Ratio1.80 Sales past 5Y-34.20% Gross Margin- 52W Low3.08% ATR0.25
Employees122 Current Ratio1.80 Sales Q/Q100.00% Oper. Margin- RSI (14)20.02 Volatility26.57% 15.17%
OptionableYes Debt/Eq7.76 EPS Q/Q72.80% Profit Margin- Rel Volume3.39 Prev Close0.49
ShortableYes LT Debt/Eq5.29 EarningsMar 27 AMC Payout- Avg Volume611.71K Price0.49
Recom3.00 SMA20-55.55% SMA50-84.23% SMA200-89.22% Volume335,815 Change0.98%
Feb-22-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-22-17Downgrade FBR & Co. Outperform → Mkt Perform $13 → $2
Aug-11-16Reiterated FBR Capital Outperform $14 → $13
Mar-30-16Reiterated Stifel Buy $16 → $10
Mar-17-16Reiterated FBR Capital Outperform $16 → $14
Mar-08-16Reiterated Needham Buy $14 → $11
Nov-17-15Reiterated Needham Buy $17 → $14
Nov-16-15Reiterated FBR Capital Outperform $19 → $17
Jun-26-15Initiated FBR Capital Outperform $19
Mar-26-15Initiated ROTH Capital Buy $21
Feb-25-15Initiated MLV & Co Buy $13
Mar-24-17 07:01PM  Lifshitz & Miller LLP Announces Investigation of Argos Therapeutics, Inc., Avid Technology, Inc., HMS Holdings Corp., Invuity, Inc., SITO Mobile, Ltd., Trevena, Inc., USANA Health Sciences, Inc. and VAALCO Energy, Inc. PR Newswire -32.60%
Mar-23-17 06:55PM  Argos receives termination notice for Centennial Campus lease at bizjournals.com -16.44%
04:31PM  ARGOS THERAPEUTICS INC Files SEC form 8-K, Termination of a Material Definitive Agreement
Mar-22-17 06:06PM  IMPORTANT ARGOS THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Argos Therapeutics, Inc. in the Middle District of North Carolina GlobeNewswire +8.61%
01:04PM  ARGOS THERAPEUTICS INC Financials
Mar-21-17 09:29AM  Argos Therapeutics, Inc. :ARGS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 -5.76%
Mar-20-17 11:56AM  ARGS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Argos Therapeutics, Inc. and a Lead Plaintiff Deadline of May 15, 2017 GlobeNewswire -15.00%
Mar-17-17 10:30PM  SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Argos Therapeutics, Inc. (ARGS) To Contact Brower Piven Before The Lead Plaintiff Deadl GlobeNewswire -16.67%
11:10AM  Durham's Argos Therapeutics may file for bankruptcy at bizjournals.com
Mar-16-17 06:50PM  Robbins Arroyo LLP: Argos Therapeutics, Inc. (ARGS) Misled Shareholders According to a Recently Filed Class Action Business Wire
04:18PM  ARGOS THERAPEUTICS INC Files SEC form 10-K, Annual Report
02:07PM  As workforce shrinks, what do job cuts mean for Argos' Durham expansion, incentives? at bizjournals.com
12:02PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Argos Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline GlobeNewswire
Mar-15-17 02:13PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Argos Therapeutics, Inc. GlobeNewswire
Mar-09-17 05:55PM  Argos to reduce workforce by nearly 40 percent at bizjournals.com -7.41%
04:31PM  ARGOS THERAPEUTICS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors or
Mar-06-17 09:00AM  ARGOS THERAPEUTICS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements and E -10.34%
Feb-27-17 06:29PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Argos Therapeutics, Inc. -- ARGS PR Newswire -12.24%
Feb-23-17 01:11PM  Biotech Movers And Shakers: Ocular Therapeutix Inc (OCUL) And Argos Therapeutics Inc (ARGS) at Insider Monkey -8.47%
11:17AM  Committee Suggests Argos Halt Cancer Drug Study at Investopedia
Feb-22-17 04:11PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Argos Therapeutics, Inc. Business Wire -66.48%
04:04PM  Argos Therapeutics, TripAdvisor Enter Wednesdays 52-Week Low Club
03:05PM  Argos stock sinks more than 65 percent following recommendation to stop trial at bizjournals.com
01:02PM  Argos Therapeutics downgraded by FBR & Co. and JMP Securities
08:58AM  Argos Therapeutics Tanks on Committee Suggestion to Stop Carcinoma Drug Study
08:57AM  Argos says independent committee predicts trial failure, shares slump Reuters
08:52AM  Argos Plummets 72%, Leads Biotech Movers
08:29AM  Argos says independent committee suggests stopping carcinoma study Reuters
08:10AM  Argos Therapeutics cancer treatment study recommended to be discontinued for futility at MarketWatch
08:06AM  ARGOS THERAPEUTICS INC Files SEC form 8-K, Other Events
08:00AM  Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review GlobeNewswire
Feb-13-17 08:30AM  Argos Therapeutics to Participate in 2017 Genitourinary Cancers Symposium GlobeNewswire
Feb-06-17 08:50AM  Is the Options Market Predicting a Spike in Argos Therapeutics (ARGS) Stock?
08:30AM  Argos Therapeutics to Participate in BIO CEO and Investor Conference GlobeNewswire
Jan-23-17 05:01PM  ARGOS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princip
08:09AM  Argos CEO talks commercialization and hiring following expansion at bizjournals.com
Jan-19-17 04:05PM  Argos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial Campus of North Carolina State University GlobeNewswire
Jan-06-17 08:00AM  Argos Therapeutics (ARGS) Looks Good: Stock Rises by 5%
Dec-27-16 12:21PM  ETFs with exposure to Argos Therapeutics, Inc. : December 27, 2016 +6.52%
Dec-19-16 08:00AM  Argos Therapeutics (ARGS) Catches Eye: Stock Jumps 5%
Dec-15-16 05:17PM  ARGOS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
Dec-14-16 08:00AM  Argos Therapeutics Enters into Strategic Research Agreement with Personalis, Inc. GlobeNewswire
Dec-13-16 12:25PM  ETFs with exposure to Argos Therapeutics, Inc. : December 13, 2016
08:30AM  Argos Therapeutics Appoints Dr. Ralph Snyderman and Irackly Mtibelishvily to the Companys Board of Directors GlobeNewswire
Dec-07-16 04:30PM  Argos Therapeutics Reports Highlights from Investor Day in New York City GlobeNewswire
Dec-01-16 08:30AM  Argos Therapeutics Opens Registration for Upcoming Investor Day GlobeNewswire
Nov-29-16 03:04PM  ETFs with exposure to Argos Therapeutics, Inc. : November 29, 2016
08:00AM  Argos Therapeutics to Participate in 2016 EORTC-AACR-NCI Symposium GlobeNewswire
Nov-28-16 09:39AM  Argos Therapeutics, Inc. :ARGS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
Nov-18-16 08:00AM  Cellthera Presents Preclinical Data at SITC Using Argos Individualized Immunotherapy GlobeNewswire
Nov-17-16 09:10AM  Edited Transcript of ARGS earnings conference call or presentation 14-Nov-16 1:30pm GMT
Nov-14-16 09:00AM  Argos Therapeutics Participating in Strategies for an HIV Cure 2016 Meeting GlobeNewswire
08:13AM  ARGOS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
07:07AM  Q3 2016 Argos Therapeutics Inc Earnings Release - Before Market Open
06:43AM  Argos Therapeutics reports 3Q loss
06:30AM  Argos Therapeutics Reports Third Quarter 2016 Financial Results and Recent Operational Highlights GlobeNewswire
Nov-11-16 08:00AM  Argos Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +5.49%
07:39AM  Drug Stocks' Q3 Earnings to Watch on Nov 14: ARGS, AST
Nov-10-16 08:30AM  Argos Therapeutics to Participate in SITC 2016 Annual Meeting GlobeNewswire
Nov-07-16 08:30AM  Argos Therapeutics to Host Third Quarter 2016 Financial Results Conference Call on Monday, November 14, 2016 GlobeNewswire
Nov-03-16 08:56AM  Argos Therapeutics Announces Publication of a Case Report on Long-term Survival of Kidney Cancer Patients Treated with AGS-003 Individualized Immunotherapy Featured in the Kidney Cancer Journal GlobeNewswire
Nov-02-16 08:00AM  Argos Therapeutics Participating in 4th International mRNA Health Conference GlobeNewswire
Oct-26-16 08:00AM  Argos Therapeutics Announces CEO Jeff Abbey Elected to NCBIO Board of Directors GlobeNewswire
Oct-19-16 08:00AM  Argos Therapeutics to Host Investor Day on Wednesday, December 7, 2016 GlobeNewswire
Oct-14-16 08:00AM  Argos Therapeutics to Participate in 2016 BIO Investor Forum GlobeNewswire
Oct-11-16 10:04AM  ETFs with exposure to Argos Therapeutics, Inc. : October 11, 2016
Oct-03-16 08:00AM  Argos Therapeutics to Participate in 2016 Cell & Gene Meeting on the Mesa GlobeNewswire -5.03%
Sep-26-16 10:20AM  ETFs with exposure to Argos Therapeutics, Inc. : September 26, 2016
Sep-13-16 09:43AM  5 Biotech Stocks That Are Broker Favorites
Sep-09-16 10:23AM  ETFs with exposure to Argos Therapeutics, Inc. : September 9, 2016 -6.85%
Sep-08-16 10:13AM  Will Argos Therapeutics (ARGS) Continue to Surge Higher?
Sep-07-16 08:30AM  Why Argos Therapeutics (ARGS) Could Be Positioned for a Surge
Sep-01-16 04:05PM  Argos Therapeutics to Participate in 23rd Annual NewsMakers in the Biotech Industry Conference GlobeNewswire
Aug-31-16 08:39AM  How Argos Therapeutics (ARGS) Stock Stands Out in a Strong Industry
Aug-29-16 11:01AM  ETFs with exposure to Argos Therapeutics, Inc. : August 29, 2016 +7.41%
Aug-18-16 04:55PM  Edited Transcript of ARGS earnings conference call or presentation 10-Aug-16 8:30pm GMT
Aug-16-16 12:01PM  ETFs with exposure to Argos Therapeutics, Inc. : August 16, 2016 -7.27%
Aug-15-16 04:17PM  ARGOS THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
01:28PM  Argos Therapeutics, Inc. :ARGS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016
Aug-10-16 04:41PM  Argos Therapeutics reports 2Q loss
04:20PM  ARGOS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
04:05PM  Argos Therapeutics Reports Second Quarter 2016 Financial Results and Recent Operational Highlights GlobeNewswire
07:07AM  Q2 2016 Argos Therapeutics Inc Earnings Release - After Market Close
Aug-09-16 09:24AM  Drug Stock Earnings to Watch on Aug 10: ONCE, COLL & ARGS
Aug-04-16 08:00AM  Argos Therapeutics to Host Second Quarter 2016 Financial Results Conference Call on Wednesday, August 10, 2016 GlobeNewswire
Jul-29-16 06:12AM  ARGOS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statem
Jul-28-16 09:23AM  Argos Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock and Warrants GlobeNewswire -16.87%
Jul-27-16 04:06PM  Argos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Jul-21-16 11:27AM  These 5 Stocks Under $10 Are Set to Soar Higher +5.07%
Jul-14-16 08:30AM  Argos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV GlobeNewswire
Jul-11-16 08:36AM  ARGOS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Finan
08:00AM  Dr. Richard D. Katz Joins Argos Therapeutics as Chief Financial Officer GlobeNewswire
Jul-05-16 12:07PM  Buy 5 Attractive Biotechs at Bargain Prices -8.39%
Jul-01-16 05:19PM  5 Top Biotech Performers of 2016 +5.06%
Jun-29-16 08:19AM  ARGOS THERAPEUTICS INC Files SEC form 8-K, Other Events
08:00AM  Argos Therapeutics Announces Closing of $29.8 Million Second Tranche of March 2016 Financing GlobeNewswire
Jun-27-16 08:00AM  Argos Therapeutics Added to the Russell 2000® Index GlobeNewswire
Jun-20-16 02:02PM  ETFs with exposure to Argos Therapeutics, Inc. : June 20, 2016
Jun-16-16 04:30PM  Argos Therapeutics Inc with Dr. Robert Figlin Call scheduled for 4:30 pm ET today
Jun-15-16 12:30PM  Durham's Argos to learn more about how its drugs affect immune system at bizjournals.com
Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its products include AGS-003, which is under Phase III clinical trials and intended for the treatment of metastatic renal cell carcinoma (clear cell); and AGS-004, which is under Phase IIb clinical trials and is intended for the treatment of Human Immunodeficiency Virus. The company also develops AGS-003 for metastatic renal cell carcinoma (non-clear cell), early stage RCC, and other solid tumors. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pharmstandard International S.10% OwnerOct 07Buy4.7321,00099,33013,242,279Oct 13 04:48 PM
Pharmstandard International S.10% OwnerOct 06Buy4.812,64012,69813,221,279Oct 13 04:48 PM
Pharmstandard International S.10% OwnerOct 05Buy4.859004,36513,218,639Oct 13 04:48 PM
Pharmstandard International S.10% OwnerOct 04Buy4.697,16433,59913,217,739Oct 13 04:48 PM
Pharmstandard International S.10% OwnerOct 03Buy4.7011,30853,14813,210,875Oct 04 04:12 PM
Pharmstandard International S.10% OwnerSep 30Buy4.7130,232142,39313,199,567Oct 04 04:12 PM
Pharmstandard International S.10% OwnerSep 29Buy4.6015,10069,46013,169,335Sep 30 04:20 PM
Pharmstandard International S.10% OwnerSep 28Buy4.5428,518129,47213,154,235Sep 30 04:20 PM
Pharmstandard International S.10% OwnerSep 20Buy4.7741,259196,80513,125,717Sep 21 07:50 PM
Pharmstandard International S.10% OwnerSep 19Buy4.765,58026,56113,084,458Sep 21 07:50 PM
Pharmstandard International S.10% OwnerSep 16Buy4.7836,632175,10113,078,578Sep 20 08:36 AM
Pharmstandard International S.10% OwnerSep 15Buy4.7615,88075,58913,041,946Sep 20 08:36 AM
Pharmstandard International S.10% OwnerSep 01Buy4.7816,97781,15013,026,066Sep 07 09:24 AM
Pharmstandard International S.10% OwnerAug 24Buy4.5557,772262,86312,953,865Aug 25 04:24 PM
Pharmstandard International S.10% OwnerAug 24Buy4.5755,224252,37413,009,089Aug 29 04:07 PM
Pharmstandard International S.10% OwnerAug 23Buy4.369,59941,85212,896,093Aug 25 04:24 PM
Pharmstandard International S.10% OwnerAug 22Buy4.2621,95093,50712,886,494Aug 23 04:43 PM
Pharmstandard International S.10% OwnerAug 19Buy4.2353,524226,40712,864,544Aug 23 04:43 PM